Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) and increased the ...

Rocket Pharmaceuticals is also progressing in its other projects, like the rolling BLA for Fanconi anemia and the Phase 1 enrollment completion in PKP2-arrhythmogenic cardiomyopathy. Furthermore, the ...

RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

The Queen Consort has shown off old and new looks on her tour with King Charles, including some of her favourite designers.

Queen Camilla's wardrobe held special significance, prominently featuring pieces from her favoured designers, Fiona Clare and ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...

Background: The exact mechanism of hyperammonemia is thought to be multifactorial, but is not yet fully understood. No studies have yet reported hyperammonemia combined with Fanconi syndrome caused by ...

SKY-1214 targets FANCL/FANCI, critical components of the Fanconi anemia DNA damage repair pathway, which MM and NHL cells use to maintain their genome integrity. Details of the presentation are as ...